Development and characterization of a cationic lipid nanocarrier as non-viral vector for gene therapy

Autor(es)

Severino, Patricia ^{[1, 2]} ; Szymanski, Marcelo ^[3] ; Favaro, Marianna ^[3] ; Azzoni, Adriano R. ^[3] ; Chaud, Marco V. ^[4] ; Santana, Maria Helena A. ^[1] ; Silva, Amelia M. ^{[5, 6]} ; Souto, Eliana B. ^{[2, 7]}

Afiliação do(s) autor(es)

^[1] Univ Campinas Unicamp, Sch Chem Engn, Dept Biotechnol Proc, BR-13083970 Campinas, SP - Brazil

^[2] Fernando Pessoa Univ UFP FCS, Fac Hlth Sci, P-4200150 Oporto - Portugal

^[3] Univ Estadual Campinas, Mol Biol & Genet Engn Ctr, Lab Genet & Mol Anal, Campinas, SP - Brazil

^[4] Sorocaba Univ, UNISO, Lab Dev & Evaluat Bioact Substance, Sorocaba, SP - Brazil

^[5] Univ Tras Os Montes & Alto Douro UTAD, Dept Biol & Environm, P-5001801 Vila Real - Portugal

^[6] Ctr Res & Technol Agroenvironm & Biol Sci CITAB U, P-5001801 Vila Real - Portugal

^[7] Univ Coimbra FFUC, Fac Pharm, P-3000548 Coimbra - Portugal

• Tipo de documento: Artigo Científico
• Fonte: European Journal of Pharmaceutical Sciences; v. 66, p. 78-82, JAN 23 2015.
• Citações Web of Science: 25

Resumo

The aim of the present work was to produce a cationic solid lipid nanoparticle (SLN) as non-viral vector for protein delivery. Cationic SLN were produced by double emulsion method, composed of softisan (R) 100, cetyltrimethylammonium bromide (CTAB), Tween (R) 80, Span (R) 80, glycerol and lipoid (R) S75 loading insulin as model protein. The formulation was characterized in terms of mean hydrodynamic diameter (z-ave), polydispersity index (PI), zeta potential (ZP), stability during storage time, stability after lyophilization, effect of toxicity and transfection ability in HeLa cells, in vitro release profile and morphology. SLN were stable for 30 days and showed minimal changes in their physicochemical properties after lyophilization. The particles exhibited a relatively slow release, spherical morphology and were able to transfect HeLa cells, but toxicity remained an obstacle. Results suggest that SLN are nevertheless promising for delivery of proteins or nucleic acids for gene therapy. (C) 2014 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 08/00421-8 - Incorporação e avaliação imunológica de antígenos tumorais incorporados em nanopartículas lipídicas sólidas e nanocarreadores lipídicos sólidos
• Beneficiário: Patricia Severino
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 11/20801-2 - Encapsulação de Polimixina B em NLS para incorporação em hidrogéis mucoadesivos para tratamento de mucosite oral
• Beneficiário: Patricia Severino
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado